Development
ADMA Biologics, Inc.
ADMA
$18.96
-$0.95-4.77%
NASDAQ
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 9.85% | 11.89% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.85% | 11.89% | |||
| Cost of Revenue | 0.46% | 3.12% | |||
| Gross Profit | 26.10% | 31.20% | |||
| SG&A Expenses | 11.92% | -2.61% | |||
| Depreciation & Amortization | 4.87% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.08% | 0.16% | |||
| Operating Income | 51.66% | 303.33% | |||
| Income Before Tax | -787.87% | 140.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -787.87% | 140.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -787.87% | 140.26% | |||
| EBIT | 51.66% | 303.33% | |||
| EBITDA | 42.30% | 159.41% | |||
| EPS Basic | -785.09% | 139.86% | |||
| Normalized Basic EPS | 159.34% | 191.00% | |||
| EPS Diluted | -894.00% | 133.33% | |||
| Normalized Diluted EPS | 171.26% | 187.00% | |||
| Average Basic Shares Outstanding | 0.31% | 1.16% | |||
| Average Diluted Shares Outstanding | -3.33% | 4.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||